Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Revolutionizing Genetic Disease Research: DLI's Vital Role in Meeting Unmet Needs, Pipeline Assessment, Disease Intelligence, Pricing, Market Access Data, and Analysis for Pharma Companies | Disease Landscape Insights

This image opens in the lightbox

News provided by

Disease Landscape Insights

26 Sep, 2023, 08:07 GMT

Share this article

Share toX

Share this article

Share toX

LONDON, Sept. 26, 2023 /PRNewswire/ -- The prevalence of genetic diseases is soaring at an alarming rate worldwide. This increased disease burden has elevated the demand for effective diseases management solutions. Most genetic ailments are complexed in nature since they are generally caused by abnormal alterations or mutation in a person's DNA. Medical researchers are making efforts to get deeper genetic disease insights and understand their underlying causes with the sole aim to simplify their management.

Genetic ailments may affect people across all age groups irrespective of their gender or other biological characteristics. The accurate detection and treatment of many such diseases is still a distant dream. Understanding genetic disease pathways can get quite challenging for medical researchers. Widespread technological advancements in the healthcare vertical have undoubtedly paved the way for these researchers to delve into the world of genetic diseases and find ways to cure them and save millions of lives. 

DiseaseLandscape Insights with its healthcare consulting abilities has been supporting medical researchers and pharma organizations in their R&D activities. It has been helping various pharma firms in solidifying their position in the genetic disease market by providing them with drug launch strategies, post launch services, commercial strategy analysis, and product pipeline analysis-based pharma consulting services.

DLI's Exhaustive Genetic Disease Consulting Repository-

DLI has been associated for genetic disease research extensively. It maintains a vast repository of epidemiology study pertaining to numerous types of genetic disorders. Here are top diseases covered by DLI as a part of its vast repository-

  • Cystic fibrosis
  • Sickle cell anemia
  • Huntington's disease.
  • Solid Tumor
  • Charcot Marie Tooth disorder
  • Angelman Syndrome
  • Albinism
  • Duchenne Muscular Dystrophy (DMD) Disease
  • Congenital Adrenal Hyperplasia
  • Others

DLI has been guiding healthcare research organizations, biotech firm, and pharma companies through overall genetic disease pipeline including genetic diseases drug discovery.  With its deep dive expertise in the field, it is also helping these concerned entities to comply with fda gene therapy guidance regulations when it comes to drug development or formulation of diagnostic solutions.

Elucidating the characteristics and symptoms of various genetic ailments-

Genetic diseases manifest diverse symptoms that may vary from person to person. The symptoms generally comprise of cognitive, behavioural, and physical complications. Growth delays, chronic aches, learning disabilities, organ dysfunctions, and the onset of physiological issues are some of the primary symptoms of these ailments.

It is notable to mention that most genetic diseases are passed down from one generation to the next through altered or mutated genes. The age of onset or severity of these ailments is not constant. Some genetic disorders may develop at an early stage whereas others may start showcasing symptoms later in life. Most of these diseases are chronic in nature and therefore cannot be cured permanently. Although DLI has been helping genetic disease experts in developing top selling rare disease drugs and eradicate such ailments.

Diagnostic Landscape-

The diagnosis of genetic ailments is not as simple as it sounds like. This is because most of these diseases are chronic and complicated in nature. Some of the noticeable symptoms may also be similar to that of non-genetic diseases, making it extremely difficult for professionals to detect the disorder accurately. But with the integration of advanced technologies in this vertical, experts have developed cutting edge diagnostic solutions. The promising results shown by these techniques are not only improving the lives of patients but are also bolstering genetic disorder market growth.

Clinical evaluation, genetic testing, biopsies, imaging tests, prenatal testing, and biochemical tests are some of the efficient genetic disorder diagnostic tools. The first and foremost step in the course of disease diagnosis is to identify the symptoms and conduct medical history assessments. Since genetic disorders are inherited conditions, getting accurate data on family medical history eases the entire diagnostic process for the healthcare professionals.

Price and Market Access

Genetic Disease Treatment-

Treatment gap identification is one of the crucial steps when it comes to the development of new treatment entities for any disease including inherited conditions.  Without analysing the existing treatment landscape, players cannot cater to genetic disease unmet needs. DiseaseLandscape Insights through its commendable research capabilities has been assisting the concerned players in their drug and therapy formulation endeavours.

Genetic disease statistics worldwide are suggesting a steep rise in the cases of genetic diseases. This has pushed medical scientists, pharma organizations, and healthcare experts to join hands and develop beneficial drugs and therapies. There are numerous gene therapies in development that are projected to revolutionize the genetic disease treatment vertical.

Apart from that, various forms of oral medications, surgeries including stem cell transplants, along with occupational and physical therapies are already showing successful results in alleviating the symptoms of genetic disorders and improvising the lives of the masses.

Pfizer rare disease drugs

DLI has been conducting in depth research on the efforts taken by well known pharma companies when in comes to rare disease treatment solutions. From their product portfolio analysis to their price and market access strategies, DLI examines it all.

As a result, DLI has discovered that Pfizer has been extensively involved in the development of treatments for various rare genetic diseases. It is known to have developed a drug named atolimod, aimed at treating Duchenne Muscular Dystrophy. Besides, it has also formulated other drug therapies for ailments such as haemophilia, Hereditary Transthyretin Amyloidosis (hATTR), and Huntington's disease, among others.

Role of DLI in Clinical Trials-

For any drug or therapy to gain commercial recognition, its efficacy, safety, and long-term feasibility are required to be assessed thoroughly. Drug developers need to put their potential products through a series of clinical trial assessments. It is worth noting that clinical trial management comes with stringent responsibilities. DLI has been a forefront in ensuring smooth conduction of clinical trials. It helps players with clinical trial feasibility analysis, regulatory compliance, protocol development, patient recruitment, data management, safety monitoring, market access, and product portfolio extension, among others. 

Apart from these trials, DLI empowers players with new product launch services, post launch services, along with price reimbursement insights to ensure that their potential drugs survive in the highly competitive market.

Pharma consulting Services

Summing Up-

DLI has been offering genetic disorder consultation to the related players to support them in their endeavours to develop effective diagnostic and treatment solutions. Inherited disorders are becoming highly prevalent across the globe, impacting people across all age groups. These diseases are complicated in nature since they are triggered by genetic alterations or mutations. It is crucial for medical experts to get comprehensive overview of such ailments so that they can identify the underlying causes and work on developing the genetic disease pipeline. By leveraging DLI's consulting services, these players are successfully conducting R&D activities and clinical trials, leading to the emergence of advanced drugs and therapies. These entities are giving a ray of hope to the genetic disease patients along with their caregivers.

About Disease Landscape: 

Disease Landscape, a pioneering company specializing in Disease Intelligence, Pricing, and Market Access. Utilizing the power of data analytics, Disease Landscape Insights is dedicated to the healthcare sector with invaluable, finely crafted insights and recommendations regarding global pricing and market access strategies. As a specialized firm, we are committed to delivering unparalleled insights into pricing and market access, custom-tailored to the healthcare and pharmaceutical industries. Our data-driven solutions and cutting-edge technology position us as your trustworthy partner, offering swift, adaptable, and evidence-based alternatives to traditional market access and pricing research methods.  

Our core competencies encompass Market Research Services, Consulting Services, Global Pricing and Market Access, Epidemiology Studies, as well as Product Portfolio and Pipeline Services. Our expertise lies in furnishing comprehensive data intelligence throughout every phase of drug and device research.  

Contact Us:  

Disease Landscape Insights LLP  
6th Floor, Sr No.207, Office A H 6070 Phase 1  
Solitaire Business Hub, Viman Nagar  
Pune, Maharashtra, 411014  
Email: ajay@diseaselandscape.com    
Email: vishal@diseaselandscape.com  
Corporate Sales: +44-2038074155 
Asia Office: +917447409162
Blog: https://www.diseaselandscape.com/blogs  
Case Study: https://www.diseaselandscape.com/casestudies   
Pharma consulting Services 
Follow Us: LinkedIn | Twitter | Facebook

Logo: https://mma.prnewswire.com/media/2217060/Disease_Landscape_Insights_Logo.jpg

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.